Articles tagged with: Revlimid
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG), as well as the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.
Therefore, it is again time to take a little quiz to test …
This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer …
The results of a small British study may lead to fewer myeloma patients suffering from diarrhea while taking Revlimid.
In a short article published last week, researchers from the Royal Marsden Hospital in London report that a condition known as “bile acid malabsorption” appears to be a frequent cause of the diarrhea experienced by some patients during treatment with Revlimid (lenalidomide).
The researchers also found that the bile acid malabsorption and resulting diarrhea in these patients can be addressed in two ways.
For some patients, reducing consumption of …
Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial comparing Kyprolis-Revlimid-dexamethasone to Revlimid-dexamethasone in patients with relapsed multiple myeloma.
Patients in the trial who received the Kyprolis-Revlimid-dexamethasone combination (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dexamethasone (Rd) (17.6 months).
There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. However, the difference is not yet statistically significant.
The results of the trial are important for two …
It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.
Quite a few presentations caught one’s eye.
We finally saw the results of the much awaited PANORAMA-1 study investigating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexamethasone compared to Velcade and dexamethasone alone.
Another study looked at …